

AB
CONT.

90. The antibody of claim 18 wherein said isolated nucleic acid molecule encodes a protein comprising the sequence of SEQUENCE ID NO: 10.

91. The antibody of claim 18 wherein said isolated nucleic acid molecule encodes a protein comprising the sequence of SEQUENCE ID NO: 12.

92. The antibody of claim 18 wherein said isolated nucleic acid molecule encodes a protein comprising the sequence of SEQUENCE ID NO: 14.

93. The antibody of claim 18 wherein said isolated nucleic acid molecule encodes a protein comprising the sequence of SEQUENCE ID NO: 16. --

REMARKS

With entry of this Preliminary Amendment, claims 18-19, 22 and 88-93 are pending in this application. By this Amendment, the specification is amended to add the section entitled "CROSS-REFERENCE TO RELATED APPLICATION" which section recites Applicants' claim to priority. Also by this Amendment, claims 18-19 are amended and new claims 88-93 are added to incorporate the subject matter of cancelled claims. None of these amendments add new matter to the application. Applicants respectfully request entry of this amendment and consideration of the present application.

Applicants believe that the application is in condition for allowance and respectfully request that the Examiner issue a Notice to that effect.

Respectfully submitted,

Seed Intellectual Property Law Group PLLC



Gary M. Myles, Ph.D.
Registration No. 46,209

GMM:cew

Enclosures:

Postcard

701 Fifth Avenue, Suite 6300
Seattle, Washington 98104-7092
Phone: (206) 622-4900
Fax: (206) 682-6031

U:\ Gary\M\client folders\Chiroscience\240083\508D2 \Divisional application\Preliminary Amendment as filed.doc